Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsBusiness

Bharat Biotech must address WHO's Covaxin suspension to avoid EUL cancellation, says MEA

In a communication to Dr V K Paul, the convenor of a key empowered group on COVID vaccination, on Tuesday the Ministry of External Affairs said many issues about vaccines and international travel by Indians have arisen and these must be addressed immediately.

April 28, 2022 / 07:51 PM IST
Bharat Biotech’s Covaxin

Bharat Biotech’s Covaxin

Weeks after WHO suspended the supply of Covaxin through UN procurement agencies, the MEA suggested that vaccine-maker Bharat Biotech addresses the issue immediately to avoid cancellation of the world health body’s emergency use approval for the jab.

In a communication to Dr V K Paul, the convenor of a key empowered group on COVID vaccination, on Tuesday the Ministry of External Affairs said many issues about vaccines and international travel by Indians have arisen and these must be addressed immediately.

"The issues pertain to m-RNA based booster dose requirement by countries which, in effect, negates our effort to obtain recognition of Covishield and Covaxin, suspension of supply of Covaxin by WHO, acceptance of Corbevax and Covaxin-based vaccination certificates for children and international travel by Indians vaccinated with Sputnik-V,” Foreign Secretary Harsh Vardhan Shringla said.

In his communication, Shringla said following an inspection of the Bharat Biotech premises on March 14 for Covaxin’s emergency use listing (EUL), WHO has announced the suspension of the vaccine’s supply through UN procurement agencies owing to deficiencies in good manufacturing practices.